The vaccine, called CIMAVAX-EGF, was first registered in 2008 in Cuba, where it was developed 15 years ago. More than a thousand Cuban patients were successfully treated by the vaccine, according to Gisela González, medical researcher from the Immunologic Molecular Center (CIM) in Havana.
Related posts:



